483 Roundup: FDA Raps Four Facilities for Quality Failures

FDA inspections revealed good manufacturing practice and other deficiencies at drug manufacturing facilities in New Jersey, Vermont and California, leading to Form 483 inspection observations for four firms.
Source: Drug GMP Report